Literature DB >> 24636534

Lymphotoxin and TNF: how it all began-a tribute to the travelers.

Nancy H Ruddle1.   

Abstract

The journey from the discoveries of lymphotoxin (LT) and tumor necrosis factor (TNF) to the present day age of cytokine inhibitors as therapeutics has been an exciting one with many participants and highs and lows; the saga is compared to that in "The Wizard of Oz". This communication summarizes the contributions of key players in the discovery of the cytokines and their receptors, the changes in nomenclature, and the discovery of the LT family's crucial role in secondary and tertiary lymphoid organs. The remarkable advances in therapeutics are detailed as are remaining problems. Finally, special tribute is paid to two pioneers in the field who have recently passed away: Byron H. Waksman and Lloyd Old.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Byron H. Waksman; Lloyd Old; Lymphotoxin; Secondary lymphoid organs; Tertiary lymphoid organs; The Wizard of Oz; Therapeutic inhibitors of LT and TNF; Tumor necrosis factor

Mesh:

Substances:

Year:  2014        PMID: 24636534      PMCID: PMC4027955          DOI: 10.1016/j.cytogfr.2014.02.001

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  80 in total

1.  Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice.

Authors:  P A Koni; R Sacca; P Lawton; J L Browning; N H Ruddle; R A Flavell
Journal:  Immunity       Date:  1997-04       Impact factor: 31.745

2.  Cloning and expression of murine lymphotoxin cDNA.

Authors:  C B Li; P W Gray; P F Lin; K M McGrath; F H Ruddle; N H Ruddle
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

3.  The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria.

Authors:  M B van Hensbroek; A Palmer; E Onyiorah; G Schneider; S Jaffar; G Dolan; H Memming; J Frenkel; G Enwere; S Bennett; D Kwiatkowski; B Greenwood
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

4.  Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization.

Authors:  B B Aggarwal; B Moffat; R N Harkins
Journal:  J Biol Chem       Date:  1984-01-10       Impact factor: 5.157

5.  Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function.

Authors:  Jeffrey L Browning; Norm Allaire; Apinya Ngam-Ek; Evangelia Notidis; Jane Hunt; Steven Perrin; Roy A Fava
Journal:  Immunity       Date:  2005-11       Impact factor: 31.745

6.  Nonredundant function of soluble LTα3 produced by innate lymphoid cells in intestinal homeostasis.

Authors:  Andrey A Kruglov; Sergei I Grivennikov; Dmitry V Kuprash; Caroline Winsauer; Sandra Prepens; Gitta Maria Seleznik; Gerard Eberl; Dan R Littman; Mathias Heikenwalder; Alexei V Tumanov; Sergei A Nedospasov
Journal:  Science       Date:  2013-12-06       Impact factor: 47.728

7.  Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis.

Authors:  P Neregård; A Krishnamurthy; S Revu; M Engström; E af Klint; A I Catrina
Journal:  Scand J Rheumatol       Date:  2013-12-09       Impact factor: 3.641

8.  A lymphotoxin-beta-specific receptor.

Authors:  P D Crowe; T L VanArsdale; B N Walter; C F Ware; C Hession; B Ehrenfels; J L Browning; W S Din; R G Goodwin; C A Smith
Journal:  Science       Date:  1994-04-29       Impact factor: 47.728

9.  MAdCAM-1 expressing sacral lymph node in the lymphotoxin beta-deficient mouse provides a site for immune generation following vaginal herpes simplex virus-2 infection.

Authors:  Kelly A Soderberg; Melissa M Linehan; Nancy H Ruddle; Akiko Iwasaki
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

10.  Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice.

Authors:  S Guerder; D E Picarella; P S Linsley; R A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

View more
  26 in total

Review 1.  Using the inbred mouse strain SPRET/EiJ to provide novel insights in inflammation and infection research.

Authors:  Steven Timmermans; Jolien Souffriau; Jolien Vandewalle; Lise Van Wyngene; Kelly Van Looveren; Tineke Vanderhaeghen; Claude Libert
Journal:  Mamm Genome       Date:  2018-06-09       Impact factor: 2.957

Review 2.  Major apoptotic mechanisms and genes involved in apoptosis.

Authors:  Yağmur Kiraz; Aysun Adan; Melis Kartal Yandim; Yusuf Baran
Journal:  Tumour Biol       Date:  2016-04-09

3.  Measurement of Tumor Necrosis Factor and Lymphotoxins.

Authors:  M Michele Hogan; Stefanie N Vogel
Journal:  Curr Protoc Immunol       Date:  2017-04-03

4.  Inflammatory pathway genes associated with inter-individual variability in the trajectories of morning and evening fatigue in patients receiving chemotherapy.

Authors:  Fay Wright; Marilyn Hammer; Steven M Paul; Bradley E Aouizerat; Kord M Kober; Yvette P Conley; Bruce A Cooper; Laura B Dunn; Jon D Levine; Gail DEramo Melkus; Christine Miaskowski
Journal:  Cytokine       Date:  2017-01-19       Impact factor: 3.861

Review 5.  Metabolic Messengers: tumour necrosis factor.

Authors:  Jaswinder K Sethi; Gökhan S Hotamisligil
Journal:  Nat Metab       Date:  2021-10-14

Review 6.  The role of lymphotoxin-α in rheumatoid arthritis.

Authors:  Tomohiro Hirose; Yuri Fukuma; Ayumu Takeshita; Keiichiro Nishida
Journal:  Inflamm Res       Date:  2018-03-14       Impact factor: 4.575

Review 7.  Lymphotoxin in physiology of lymphoid tissues - Implication for antiviral defense.

Authors:  Ekaterina P Koroleva; Yang-Xin Fu; Alexei V Tumanov
Journal:  Cytokine       Date:  2016-09-09       Impact factor: 3.861

8.  Repetitive ischemic injuries to the kidneys result in lymph node fibrosis and impaired healing.

Authors:  Omar H Maarouf; Mayuko Uehara; Vivek Kasinath; Zhabiz Solhjou; Naima Banouni; Baharak Bahmani; Liwei Jiang; Osman A Yilmam; Indira Guleria; Scott B Lovitch; Jane L Grogan; Paolo Fiorina; Peter T Sage; Jonathan S Bromberg; Martina M McGrath; Reza Abdi
Journal:  JCI Insight       Date:  2018-07-12

9.  cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes.

Authors:  Kevin Roehle; Li Qiang; Katherine S Ventre; Daniel Heid; Lestat R Ali; Patrick Lenehan; Max Heckler; Stephanie J Crowley; Courtney T Stump; Gabrielle Ro; Anže Godicelj; Aladdin M Bhuiyan; Annan Yang; Maria Quiles Del Rey; Tamara Biary; Adrienne M Luoma; Patrick T Bruck; Jana F Tegethoff; Svenja L Nopper; Jinyang Li; Katelyn T Byrne; Marc Pelletier; Kai W Wucherpfennig; Ben Z Stanger; James J Akin; Joseph D Mancias; Judith Agudo; Michael Dougan; Stephanie K Dougan
Journal:  Sci Transl Med       Date:  2021-05-19       Impact factor: 19.319

Review 10.  Lymphotoxin: from the physiology to the regeneration of the thymic function.

Authors:  Alexia Borelli; Magali Irla
Journal:  Cell Death Differ       Date:  2021-07-22       Impact factor: 12.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.